$AFAM (Almost Family Inc.)

$AFAM {{ '2016-10-17T14:45:03+0000' | timeago}} • Announcement

$AFAM agreed to buy a controlling interest in entity holding the home health and hospice assets of $CYH for $128MM. With completion, $AFAM will operate 340 branches across 26 states and its annual net revenue run rate is expected to exceed $800MM mark. The purchase will add to $AFAM's EPS in 2017 and deal will close during 4Q16.

$MCK {{ '2017-07-21T16:07:44+0000' | timeago}} • Announcement

Biologics, a unit of healthcare technology firm $MCK, said it will join the limited distribution network of $PBYI to promote the latter’s kinase inhibitor Nerlynx. The formulation is indicated for treatment of adult patients with early-stage HER2 overexpressed/amplified breast cancer.

$REGN {{ '2017-07-21T15:50:38+0000' | timeago}} • Announcement

$REGN and $SNY announced that the European Medicine Agency's Committee for Medicinal Products for Human Use has given a positive opinion for the marketing authorization of Dupixent (dupilumab), recommending its approval in Europe for use in adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy.

$GSK {{ '2017-07-21T15:28:58+0000' | timeago}} • Announcement

$GSK and $INVA announced a submission to the European Medicines Agency (EMA) for the extended use of once-daily Relvar Ellipta in patients with controlled asthma on an inhaled corticosteroid (ICS) / long-acting β2-agonist (LABA).

$MRK {{ '2017-07-21T15:21:07+0000' | timeago}} • Announcement

President Donald Trump announced that pharma giants $MRK and $PFE are collaborating with Gorilla Glass manufacturer Corning ($GLW) for manufacturing a new glass (Valor Glass), which is superior and reliable for the delivery of injectable drugs. Corning is planning to initially invest $500MM creating 1,000 jobs at 3 facilities in US.

$ABT {{ '2017-07-20T19:55:45+0000' | timeago}} • Webcast

For 3Q17, $ABT expects adjusted EPS of $0.64-0.66, with operational sales growth expected in the mid-single digits. At current exchange rates, the company expects operational sales growth to have a negative YoY impact of around 0.5%.

$ABT {{ '2017-07-20T19:45:56+0000' | timeago}} • Webcast

$ABT said that on a comparable operational basis, 3Q17 Established Pharmaceuticals sales growth is expected in the high double-digit, while in Nutrition, sales growth is expected in low single-digit. In Diagnostics, $ABT expects sales to increase mid-to-high single digits and in Medical Devices, sales is expected to increase double-digits.

$ABT {{ '2017-07-20T17:49:19+0000' | timeago}} • Announcement

$ABT raised its full year profit forecast backed by the intention of closing the Alere acquisition in 2017. The company raised its FY17 adjusted earnings from continuing operations guidance by $0.03 to a range of $2.43-2.53 per share. Reported EPS forecast was also raised from the range of $0.92-1.02 to $1.03-1.13, reflecting double-digit growth.

$ABT {{ '2017-07-20T17:36:53+0000' | timeago}} • Announcement

Declining operating earnings and rising costs and expenses hit $ABT 2Q17 earnings as much as 54%. Earnings plunged to $283MM or $0.15 from $615MM or $0.40 per share a year earlier. Sales, however, surged 24.4% on St. Jude Medical acquisition. On an adjusted basis, $ABT reported EPS above its previous guidance range at $0.62 per share.

$MRK {{ '2017-07-20T14:29:27+0000' | timeago}} • Announcement

$MRK announced that the U.S. Food and Drug Administration (FDA) has granted tentative approval for its 100 units/mL insulin glargine injection, a follow-on biologic basal insulin in a pre-filled dosing device.

$ABT {{ '2017-07-20T12:52:57+0000' | timeago}} • Infographic

$ABT Abbott Laboratories Earnings AlphaGraphic: Q2 2017 Highlights

$AGN {{ '2017-07-19T15:54:53+0000' | timeago}} • Announcement

$AGN appointed Joseph Boccuzi to its BoD, effective immediately. Boccuzi recently retired as a Partner in the Global Life Sciences, Board and Chief Executive Officer Practices at Spencer Stuart, following 24 years of service with the global executive search and leadership consulting firm.

$ABT {{ '2017-07-17T12:36:21+0000' | timeago}} • Announcement

$ABT is commencing a tender offer to purchase for cash all outstanding shares of Series B Convertible Perpetual Preferred Stock of Alere Inc. at a price of $402 per share of Preferred Stock. The offer will expire at 11:59 pm, NYC time, on Aug 11, 2017. There is no financing condition to the offer.

$AMGN {{ '2017-07-13T12:24:26+0000' | timeago}} • Announcement

$AMGN and $AGN announced they will discuss data supporting the ABP 215 Biologics License Application (BLA) with FDA's Oncologic Drugs Advisory Committee. ABP 215 is a biosimilar candidate to Avastin (bevacizumab) and is the first bevacizumab biosimilar candidate to be considered by the FDA.

$ABT {{ '2017-07-13T12:23:21+0000' | timeago}} • Announcement

$ABT and Bigfoot Biomedical agreed to develop and commercialize diabetes management systems, integrating $ABT's FreeStyle Libre glucose sensing technology with Bigfoot's insulin delivery solutions in the United States. $ABT will provide Bigfoot with the next generation of its FreeStyle Libre glucose sensing technology.

$AGN {{ '2017-07-10T16:14:16+0000' | timeago}} • Announcement

$AGN announced additional results of a prespecified prospective pooled subgroup analysis from the two Phase 3 studies, which evaluated the efficacy and safety of Viberzi to treat the symptoms associated with irritable bowel syndrome with diarrhea, abdominal pain and diarrhea.

$PRSC {{ '2017-07-07T15:47:58+0000' | timeago}} • Announcement

$PRSC has appointed Jeff Felton as the CEO of its subsidiary LogistiCare Solutions, LLC, effective July 10, 2017. He most recently served as President of McKesson Connected Care and Analytics and he has also worked at Cardinal Health, Baxter Healthcare and Procter and Gamble.

$MRK {{ '2017-07-06T12:50:08+0000' | timeago}} • Announcement

Pharma company $MRK will present its HIV portfolio and pipeline at the 9th IAS Conference on HIV Science. The presentations include late-breaker abstracts from two phase-3 pivotal clinical trials and a phase-1 study of MK-8591, Merck’s investigational nucleoside reverse transcriptase translocation inhibitor in adult patients with HIV-1 infection.

$MRK {{ '2017-07-05T22:11:39+0000' | timeago}} • Announcement

$MRK said the US FDA has placed a clinical hold on KEYNOTE-183, KEYNOTE-185 and KEYNOTE-023, three combination studies of KEYTRUDA (pembrolizumab), the company’s anti-PD-1 therapy, in the blood cancer multiple myeloma. The FDA has determined that the risks of KEYTRUDA outweigh any potential benefit for patients with multiple myeloma.

$USPH {{ '2017-06-29T19:00:45+0000' | timeago}} • Webcast

$USPH estimates its corporate office costs, as a percentage of revenue, will be in the upper 8% to lower 9% range this year. The company said its recently adopted accounting standard and a change in the value of restricted share grants resulted in tax credit in 1Q17. The current focus is on acquisition-related opportunities to sustain growth.

$USPH {{ '2017-06-29T18:56:30+0000' | timeago}} • Webcast

$USPH expects its newly-launched analytics tool to bear good fruit as the year progresses. The company intends to continue consolidation of its smaller partnerships. The visits per clinic per day progressed sequentially in 1Q17 and has continued to progress well.

Recent Transcripts

ABT (Abbott Laboratories)
Thursday, July 20 2017 - 1:00pm
USPH (US Physical Therapy Inc.)
Thursday, June 29 2017 - 2:30pm
MCK (McKesson Corporation)
Thursday, May 18 2017 - 9:00pm
PMC (PharMerica Corporation)
Wednesday, May 10 2017 - 2:00pm
PRSC (Providence Service Corp.)
Wednesday, May 10 2017 - 12:00pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
OPK (Opko Health, Inc.)
Tuesday, May 9 2017 - 8:30pm
ADUS (Addus HomeCare Corporation)
Tuesday, May 9 2017 - 1:00pm
AGN (Allergan plc)
Tuesday, May 9 2017 - 12:30pm
PETS (PetMed Express, Inc.)
Monday, May 8 2017 - 12:30pm
FVE (Five Star Quality Care Inc.)
Friday, May 5 2017 - 2:00pm
DVCR (Diversicare Healthcare Services Inc.)
Friday, May 5 2017 - 12:30pm
LHCG (LHC Group, Inc.)
Thursday, May 4 2017 - 3:00pm
KND (Kindred Healthcare Inc.)
Thursday, May 4 2017 - 1:00pm
AMED (Amedisys Inc.)
Wednesday, May 3 2017 - 3:00pm
CSU (Capital Senior Living Corp.)
Tuesday, May 2 2017 - 9:00pm
CVS (CVS Health Corporation)
Tuesday, May 2 2017 - 12:30pm
MRK (Merck & Co. Inc.)
Tuesday, May 2 2017 - 12:00pm
CHE (Chemed Corp.)
Thursday, April 27 2017 - 2:00pm
GSK (GlaxoSmithKline plc)
Wednesday, April 26 2017 - 1:00pm

AlphaGraphics you may like